Yamamoto M, Tamura A, Kirino T, Hirakawa M, Shimizu M, Sano K
Department of Pharmacology, Yamanouchi Pharmaceutical Co. Ltd., Tokyo, Japan.
Stroke. 1989 Aug;20(8):1089-91. doi: 10.1161/01.str.20.8.1089.
We observed the effects of a new thyrotropin-releasing hormone analogue, YM-14673 (N alpha-[[(S)-4-oxo-2-azetidinyl]carbonyl]-L-histidyl-L-prolinamide dihydrate) on behavioral changes in 26 rats subjected to middle cerebral artery occlusion. The administration of 0.1 mg/kg i.p. YM-14673 was started 1 week after occlusion and was repeated daily for 2 weeks. YM-14673 significantly accelerated the recovery of neurologic deficits and ameliorated the disturbance of passive avoidance learning. Thus, YM-14673 improved behavioral response in a model of chronic focal cerebral ischemia. The availability of a chronic middle cerebral artery occlusion model for the evaluation of drugs is also discussed.
我们观察了一种新型促甲状腺激素释放激素类似物YM-14673（Nα-[[(S)-4-氧代-2-氮杂环丁烷基]羰基]-L-组氨酰-L-脯氨酰胺二水合物）对26只大脑中动脉闭塞大鼠行为变化的影响。在闭塞1周后开始腹腔注射0.1mg/kg的YM-14673，每日重复给药，持续2周。YM-14673显著加速了神经功能缺损的恢复，并改善了被动回避学习障碍。因此，YM-14673改善了慢性局灶性脑缺血模型中的行为反应。还讨论了慢性大脑中动脉闭塞模型在药物评价中的可用性。
